| | 608141-41-9 Basic information More.. |
| Product Name: | Apremilast | | Synonyms: | (S)-N-(2-(1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide;ApreMilast,CC-10004;AcetaMide, N-[2-[(1S)-1-(3-ethoxy-4-Methoxyphenyl)-2-(Methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]-;(S)-N-(2-(1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl)acetamide Apremilast (CC-10004;(S)-N-(2-(1-(3-Ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl)-1,3-dioxoisoindolin-4-yl);Apremilast (S)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione;Appleton West;N-[2-[(1S)-1-(3ethoxy-4-methoxyphenyl)-2-(methylsulfonyl)ethyl]-2,3-dihydro-1,3-dioxo-1H-isoindol-4-yl]acetamide | | CAS: | 608141-41-9 | | MF: | C22H24N2O7S | | MW: | 460.5 | | EINECS: | 807-237-6 | | Mol File: | 608141-41-9.mol |  |
Use
Apremilast (Otezla) was approved by the FDA on March 21, 2014 for the treatment of adult patients with active psoriatic arthritis. Apremilast is a member of a new class of oral small molecule inhibitors of the phosphosphodiesterase 4 (PDE4) enzyme. When PDE4 is inhibited in immune cells, it results in elevation of intracellular cyclic adenosine monophosphate (cAMP) levels, which can regulate inflammatory mediators. The current clinical data indicate that apremilast is an effective and well tolerated option for the management of psoriasis and PsA in adults.
- Apremilast
-
- US $0.00 / Kg/Bag
- 2024-05-23
- CAS:608141-41-9
- Min. Order: 2Kg/Bag
- Purity: 99% up
- Supply Ability: 20 tons
- Apremilast
-
- US $0.00-0.00 / KG
- 2024-05-23
- CAS:608141-41-9
- Min. Order: 1KG
- Purity: 99
- Supply Ability: 50000KG/month
- Apremilast
-
- US $0.00 / kg
- 2024-05-20
- CAS:608141-41-9
- Min. Order: 1kg
- Purity: 98% HPLC
- Supply Ability: 1000 kgs
|
|
608141-41-9
Recommend Suppliers |
|